NVUS Novus Therapeutics Inc.
0.8
+0.02 (+3%)
Previous Close
0.78
Open
0.75
Price To Book
0.64
Market Cap
10,379,938
Shares
12,974,923
Volume
10,529
Short Ratio
Av. Daily Volume
67,618
NewsSee all news
-
Novus Therapeutics to Participate in Two Upcoming Investor Conferences
Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 3 trial discontinued July 2016 due to poor data
Galeterone - ARMOR3-SV
Cancer - castration-resistant prostate cancer (CRPC)
Announced in August 2016 that Phase 2 trial enrollment has been discontinued.
Galeterone - ARMOR2
Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)
Phase 1 data presented June 11, 2019, 1pm.
OP0201- C-002
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolearbility objectives met.
OP0201 C-001
Healthy volunteers
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201
Acute Otitis Media - adults
Phase 1 data released April 22, 2019. Safety and tolerability objectives met.
OP0201 - C-001
Healthy volunteers
Latest News
-
Novus Therapeutics to Participate in Two Upcoming Investor Conferences
Novus Therapeutics, Inc. (NASDAQ:NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate